« NanoCrystal技術 | メイン | 利害の対立 »

利害の対立

Arthritis & Rheumatism誌に掲載された抗TNF-α剤の臨床試験の報告で、著者とスポンサーの会社の金銭の授受が以下のように詳細に記されています。これぐらい詳細に書いてもらうと、逆にどうてもよくなってきます。

Dr. Breedveld has received consulting fees or honoraria (less than $10,000 per year) from Centocor, Schering-Plough, Amgen/Wyeth, and Abbott. Dr. Weisman has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Bristol-Myers Squibb, Centocor, Amgen/Wyeth, Roche, Human Genome Sciences, Elan/Biogen, Regeneron, and Genentech. Dr. Kavanaugh has performed clinical studies for Abbott, Amgen, Centocor, Biogen-Idec, Bristol-Myers Squibb, and Genentech. Dr. Cohen has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Genentech, Biogen IDEC, Scios, Amgen, Sanofi-Aventis, Chelsea Therapeutics, and Xencor. Dr. van Vollenhoven has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Centocor, Schering-Plough, and Wyeth. Dr. Sharp has received consulting fees or honoraria (more than $10,000 per year) from Abbott, Amgen, Aventis, Centocor, Fujisawa, and Wyeth and consulting fees or honoraria (less than $10,000 per year) from Bristol-Myers Squibb and Schering. Dr. Perez is a member of Abbott's stock retirement plan. Dr. Spencer-Green owns stock in Abbott.

トラックバック

このエントリーのトラックバックURL:
http://biotodayblog.jcity.com/mt-tb.cgi/137

コメントを投稿